Phase I oncology trials: risks and benefits vary by trial type

By  

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1660-1664

Bentham Science Publishers

Access to resources Recommend Favorite

A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology

By Comets Emmanuelle   Zohar Sarah  

Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. : 387-395

Adis International

Access to resources Recommend Favorite

Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

By Onar Arzu   Kocak Mehmet   Boyett James  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 437-455

Taylor & Francis Ltd

Access to resources Recommend Favorite

Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

By Sargent Daniel  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 556-562

Taylor & Francis Ltd

Access to resources Recommend Favorite